BioArctic

BioArctic OCF Margin

The Operating Cash Flow Margin of BioArctic (BIOA B.ST) as of Sep 25, 2026 is 71.59 %. In the previous year, Operating Cash Flow Margin was -122.92 % — a change of -158.24% (higher).

OCF Margin

71.59 %

YoY

-158.24%

Last updated:

Operating Cash Flow Margin of BioArctic is 2026 71.59 % . Operating Cash Flow Margin of BioArctic was 2025 -122.92 % . It decreases by -158.24% higher compared to the previous year.

The BioArctic OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
-28.02 SEK
Jan 1, 2019
116.11 SEK
Jan 1, 2020
-148.11 SEK
Jan 1, 2021
-606.83 SEK
Jan 1, 2022
-13.86 SEK
Jan 1, 2023
50.28 SEK
Jan 1, 2024
-122.92 SEK
Jan 1, 2025
71.59 SEK
The BioArctic OCF Margin history
YEAROCF MarginYoY
71.59 %-158.24%
-122.92 %-344.49%
50.28 %-462.77%
-13.86 %-97.72%
-606.83 %+309.72%
-148.11 %-227.56%
116.11 %-514.38%
-28.02 %-70.87%
-96.18 %-115.05%
639.25 %-1,717.11%
-39.53 %—
Access this data via the Eulerpool API

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Operating Cash Flow Margin of BioArctic is 71.59 % in 2026.

Operating Cash Flow Margin of BioArctic changed from -122.92 % to 71.59 %, representing a -158.24% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin BioArctic since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's BioArctic with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

Margins — BioArctic

All Key Metrics — BioArctic